Endothelin subtype A receptor antagonist induces osteopenia in growing rats

Hirokazu Tsukahara, Chikahide Hori, Masahiro Hiraoka, Kazutaka Yamamoto, Yasushi Ishii, Mitsufumi Mayumi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Previous studies suggested that endothelin (ET) peptides are involved in bone metabolism. We examined the effects of long-term blockade of the ET(A) receptor, a receptor subtype primarily involved in the anabolic actions of ET, on bone mineral status in growing rats. Eight-week-old rats injected intraperitoneally with FR139317 50 mg/kg body weight, a specific ET(A) receptor antagonist, for 2 or 4 weeks were compared with control rats injected with vehicle only. Treatment with FR139317 caused a significant decrease in bone mass in the lumbar spine as determined by dual-energy x-ray absorptiometry (DXA). FR139317-induced osteopenia was associated with a significant decrease in the serum osteocalcin concentration but no change in the urinary excretion of pyridinium cross-links of collagen. Our findings indicate that long-term blockade of the ET(A) receptor reduces bone formation and induces osteopenia in growing rats. Our results suggest that ET produced by vascular endothelial cells plays an important role in bone growth and metabolism in vivo.

Original languageEnglish
Pages (from-to)1403-1407
Number of pages5
JournalMetabolism: Clinical and Experimental
Volume47
Issue number11
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Metabolic Bone Diseases
Endothelins
Endothelin A Receptors
Bone and Bones
Bone Development
Osteocalcin
Osteogenesis
Minerals
Spine
Collagen
Endothelial Cells
Body Weight
X-Rays
Peptides
Endothelin A Receptor Antagonists
Serum
FR 139317

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Tsukahara, H., Hori, C., Hiraoka, M., Yamamoto, K., Ishii, Y., & Mayumi, M. (1998). Endothelin subtype A receptor antagonist induces osteopenia in growing rats. Metabolism: Clinical and Experimental, 47(11), 1403-1407.

Endothelin subtype A receptor antagonist induces osteopenia in growing rats. / Tsukahara, Hirokazu; Hori, Chikahide; Hiraoka, Masahiro; Yamamoto, Kazutaka; Ishii, Yasushi; Mayumi, Mitsufumi.

In: Metabolism: Clinical and Experimental, Vol. 47, No. 11, 1998, p. 1403-1407.

Research output: Contribution to journalArticle

Tsukahara, H, Hori, C, Hiraoka, M, Yamamoto, K, Ishii, Y & Mayumi, M 1998, 'Endothelin subtype A receptor antagonist induces osteopenia in growing rats', Metabolism: Clinical and Experimental, vol. 47, no. 11, pp. 1403-1407.
Tsukahara, Hirokazu ; Hori, Chikahide ; Hiraoka, Masahiro ; Yamamoto, Kazutaka ; Ishii, Yasushi ; Mayumi, Mitsufumi. / Endothelin subtype A receptor antagonist induces osteopenia in growing rats. In: Metabolism: Clinical and Experimental. 1998 ; Vol. 47, No. 11. pp. 1403-1407.
@article{5e4a2f42087c469694426f7edec0967f,
title = "Endothelin subtype A receptor antagonist induces osteopenia in growing rats",
abstract = "Previous studies suggested that endothelin (ET) peptides are involved in bone metabolism. We examined the effects of long-term blockade of the ET(A) receptor, a receptor subtype primarily involved in the anabolic actions of ET, on bone mineral status in growing rats. Eight-week-old rats injected intraperitoneally with FR139317 50 mg/kg body weight, a specific ET(A) receptor antagonist, for 2 or 4 weeks were compared with control rats injected with vehicle only. Treatment with FR139317 caused a significant decrease in bone mass in the lumbar spine as determined by dual-energy x-ray absorptiometry (DXA). FR139317-induced osteopenia was associated with a significant decrease in the serum osteocalcin concentration but no change in the urinary excretion of pyridinium cross-links of collagen. Our findings indicate that long-term blockade of the ET(A) receptor reduces bone formation and induces osteopenia in growing rats. Our results suggest that ET produced by vascular endothelial cells plays an important role in bone growth and metabolism in vivo.",
author = "Hirokazu Tsukahara and Chikahide Hori and Masahiro Hiraoka and Kazutaka Yamamoto and Yasushi Ishii and Mitsufumi Mayumi",
year = "1998",
language = "English",
volume = "47",
pages = "1403--1407",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Endothelin subtype A receptor antagonist induces osteopenia in growing rats

AU - Tsukahara, Hirokazu

AU - Hori, Chikahide

AU - Hiraoka, Masahiro

AU - Yamamoto, Kazutaka

AU - Ishii, Yasushi

AU - Mayumi, Mitsufumi

PY - 1998

Y1 - 1998

N2 - Previous studies suggested that endothelin (ET) peptides are involved in bone metabolism. We examined the effects of long-term blockade of the ET(A) receptor, a receptor subtype primarily involved in the anabolic actions of ET, on bone mineral status in growing rats. Eight-week-old rats injected intraperitoneally with FR139317 50 mg/kg body weight, a specific ET(A) receptor antagonist, for 2 or 4 weeks were compared with control rats injected with vehicle only. Treatment with FR139317 caused a significant decrease in bone mass in the lumbar spine as determined by dual-energy x-ray absorptiometry (DXA). FR139317-induced osteopenia was associated with a significant decrease in the serum osteocalcin concentration but no change in the urinary excretion of pyridinium cross-links of collagen. Our findings indicate that long-term blockade of the ET(A) receptor reduces bone formation and induces osteopenia in growing rats. Our results suggest that ET produced by vascular endothelial cells plays an important role in bone growth and metabolism in vivo.

AB - Previous studies suggested that endothelin (ET) peptides are involved in bone metabolism. We examined the effects of long-term blockade of the ET(A) receptor, a receptor subtype primarily involved in the anabolic actions of ET, on bone mineral status in growing rats. Eight-week-old rats injected intraperitoneally with FR139317 50 mg/kg body weight, a specific ET(A) receptor antagonist, for 2 or 4 weeks were compared with control rats injected with vehicle only. Treatment with FR139317 caused a significant decrease in bone mass in the lumbar spine as determined by dual-energy x-ray absorptiometry (DXA). FR139317-induced osteopenia was associated with a significant decrease in the serum osteocalcin concentration but no change in the urinary excretion of pyridinium cross-links of collagen. Our findings indicate that long-term blockade of the ET(A) receptor reduces bone formation and induces osteopenia in growing rats. Our results suggest that ET produced by vascular endothelial cells plays an important role in bone growth and metabolism in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0031724431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031724431&partnerID=8YFLogxK

M3 - Article

C2 - 9826221

AN - SCOPUS:0031724431

VL - 47

SP - 1403

EP - 1407

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 11

ER -